Avance Clinical Wins Excellence in Business Award 2021
May 21, 2021
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical has won the Fast Movers SA Excellence in Business Award 2021 sponsored by international accounting and business advisory firm BDO.
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical has won the Fast MoversSAExcellence in Business Award 2021 sponsored by international accounting and business advisory firm BDO.
According to BDO the Fast Movers SA Excellence in Business Award, recognises a company that has achieved exceptional and sustained growth year on year, and demonstrates innovative strategies and market leadership, as shown by leading CRO Avance Clinical.
“BDO is proud to be involved with an awards program that recognises South Australia’s fastest growing, most innovative and arguably smartest businesses. Avance Clinical CEO Yvonne Lungershausen and her team focus on providing quality services while maintaining a global perspective but also a local South Australian focus – particularly as an employer of choice, making them a worthy winner of this award,” says Rudy Pieck, Managing Partner, BDO South Australia.
Avance Clinical CEO Yvonne Lungershausen, said
“As the Australian CRO for biotechs we are very pleased to be recognised for our business excellence,” she said.
“The Fast Movers Excellence in Business Award is recognition of the quality work conducted by Avance Clinical, and how we manage our growth trajectory as we continue to attract biotechs from around the world for clinical research services.
It really is all about our staff and how we support and nurture them with a team environment, training, and career progression and, most importantly, the time and resources to deliver the very best for our clients.
Australia is highly regarded around the globe for quality clinical research, rapid start-up, and the world’s most attractive rebate of 43.5% on clinical trial spend.
Biotechs from the US, Asia and EU are discovering the enormous benefits of conducting their clinical research in Australia and, perhaps most importantly, that our clinical data is accepted by all the major international regulatory authorities.”